Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Lung-Heart Toxicity in a Randomized Clinical Trial of Hypofractionated Image Guided Radiation Therapy for Breast Cancer

Hilde Van Parijs
,
Elsa Cecilia-Joseph
,
Olena Gorobets
,
Guy Storme
ORCID logo ,
Nele Adriaenssens
,
Benedicte Heyndrickx
,
Claire Verschraegen
,
Nam P. Nguyen
,
Mark De Ridder
ORCID logo ,
Vincent Vinh-Hung
* ORCID logo
Version 1 : Received: 9 December 2022 / Approved: 13 December 2022 / Online: 13 December 2022 (01:17:52 CET)

A peer-reviewed article of this Preprint also exists.

Van Parijs, H.; Cecilia-Joseph, E.; Gorobets, O.; Storme, G.; Adriaenssens, N.; Heyndrickx, B.; Verschraegen, C.; Nguyen, N.P.; De Ridder, M.; Vinh-Hung, V. Lung-Heart Toxicity in a Randomized Clinical Trial of Hypofractionated Image Guided Radiation Therapy for Breast Cancer. Frontiers in Oncology 2023, 13, doi:10.3389/fonc.2023.1211544. Van Parijs, H.; Cecilia-Joseph, E.; Gorobets, O.; Storme, G.; Adriaenssens, N.; Heyndrickx, B.; Verschraegen, C.; Nguyen, N.P.; De Ridder, M.; Vinh-Hung, V. Lung-Heart Toxicity in a Randomized Clinical Trial of Hypofractionated Image Guided Radiation Therapy for Breast Cancer. Frontiers in Oncology 2023, 13, doi:10.3389/fonc.2023.1211544.

Abstract

TomoBreast hypothesized that hypofractionated 15 fractions/3 weeks image-guided radiation therapy (H-IGRT) can reduce lung-heart toxicity, as compared with normofractionated 25-33 fractions/5-7 weeks conventional radiation therapy (CRT). 123 women with stage I-II operated breast cancer were randomized to receive CRT (N=64) or H-IGRT (N=59). The primary endpoint used a four-items measure of the time to 10% alteration in any of patient self-reported measure, physician clinical evaluation, echocardiography or lung function tests, analyzed by intention-to-treat without exclusion. Results found comparable survivals, but H-IGRT significantly reduced the toxicity measured by lung diffusion capacity and alveolar volume as compared with CRT, G1 in 53% (31/59) versus 72% (44/61) patients, P=0.006; G2, 29% versus 48%, P=0.020. H-IGRT significantly reduced the risk of composite cardio-pulmonary alteration at 5 years, 10.2% versus 26.7%, P=0.024. In conclusion, TomoBreast is a proof-of-concept that image-guided radiation-therapy can improve the overall balance of lung-heart outcomes in breast cancer adjuvant therapy. Furthermore, the significance of the findings supports the efficacy of a small trial size design, which can be critical when clinical research resources are limited.

Keywords

Breast; Targeted Radiotherapy; Lung injury; Heart injuries; Health-Related Quality Of Life; Irradiation toxicity.

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.